AusperBio
Develops oligonucleotide therapeutics targeting chronic hepatitis B
$120MSeries C
Role not disclosedLoading investors…
Loading investors…
Activity from announced rounds
Develops oligonucleotide therapeutics targeting chronic hepatitis B
Develops immunotherapies that selectively deplete cytotoxic T cells to treat autoimmune diseases
Develops human-derived antibody therapeutics for atopic dermatitis and inflammatory disease
Develops fungal genome-derived therapeutics for organ transplant rejection
Develops treatments for serious respiratory diseases
Develops bispecific antibody therapies for retinal vascular diseases including diabetic macular edema and wet AMD
Develops broad-spectrum antiviral prophylactic therapies for respiratory infections
Develops hormonal and non-hormonal male contraceptives for men and couples globally
Clinical-stage company developing neonatal cardiac progenitor cell therapies for Duchenne-associated cardiomyopathy
Develops inobrodib, a first-in-class oral p300/CBP inhibitor for relapsed or refractory multiple myeloma
Develops highly targeted, small molecule medicines for cancer and rare diseases
Develops first- and best-in-class antibody-drug conjugates (ADCs) for cancer treatment
Provides CAR-T and other advanced treatment delivery in community outpatient settings
Advancing next-generation therapeutics for migraine and other headache disorders
Developing a next-generation pertussis vaccine candidate BPZE1
Develops inhaled therapies for severe respiratory diseases
Develops medicines targeting historically undruggable protein targets in cancer